Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Clinical Improvement in Rheumatoid Arthritis Is Associated with Healthier Microvascular Function in Patients Who Respond to Antirheumatic Therapy

BERNAT GALARRAGA, JILL J.F. BELCH, TOM PULLAR, SIMON OGSTON and FAISEL KHAN
The Journal of Rheumatology March 2010, 37 (3) 521-528; DOI: https://doi.org/10.3899/jrheum.090417
BERNAT GALARRAGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Lauberdoc@hotmail.com
JILL J.F. BELCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOM PULLAR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIMON OGSTON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FAISEL KHAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) mortality. Microvascular endothelial dysfunction occurs early in the development of CV disease and is worsened by inflammation. The effect of drug treatment for RA on microvascular function has been poorly studied. We assessed the effect of antirheumatic treatment on microvascular endothelial function in patients with RA, particularly to examine responders versus nonresponders to therapy.

Methods. Fifty-one patients with active RA and no previous history of CV disease were assessed at baseline and after 2 and 4 months’ therapy with either anti-tumor necrosis factor-α drugs (etanercept, n = 27, adalimumab, n = 3) or methotrexate, n = 21. RA disease activity, inflammatory measures, and skin microvascular responses, measured using laser Doppler imaging after iontophoretic delivery of acetylcholine (ACh) and sodium nitroprusside (SNP), were assessed at each study visit.

Results. Disease Activity Score (DAS28) decreased significantly from baseline to visit 2 and 3 (6.04 ± 1.2, 4.34 ± 1.3, 4 ± 1.3, respectively; p < 0.0001). Endothelium-dependent (ACh) and independent (SNP) responses for the whole cohort did not improve significantly after drug treatment (p = 0.250, p = 0.062, respectively). When patients who responded to antirheumatic therapy (n = 31) were analyzed, there were significant improvements in both ACh (p = 0.028) and SNP responses (p = 0.019).

Conclusion. Microvascular endothelial function improves in patients who respond to antirheumatic therapy. These results support the importance of effective therapy for RA patients in terms of CV effects, which might extrapolate to reduced CV events in the future. Clinical trial registration no. ISRCTN57761809.

  • RHEUMATOID ARTHRITIS
  • CARDIOVASCULAR DISEASE
  • ETANERCEPT
  • METHOTREXATE
  • ADALIMUMAB

Cardiovascular (CV) mortality and morbidity is increased in patients with rheumatoid arthritis (RA)1–3. Although traditional risk factors contribute to this excess risk, recent evidence suggests that inflammation plays an important role4. Endothelial dysfunction occurs early in atherosclerosis and is independently associated with future CV events5,6. Several methods have been devised to measure the integrity of the endothelium, particularly by imaging of large and small blood vessels and by measuring biomarkers7–10.

Numerous studies have demonstrated endothelial dysfunction in the macrocirculation and its correlation with CV risk11–13; recent interest has focused on the microvascular bed and its role as a predictor of CV events14–16. Indeed, some authors suggest that microvascular involvement may occur earlier than macrovascular dysfunction in the course of atherosclerosis12,17, making it an interesting early surrogate marker of CV disease (CVD). Given that microvascular dysfunction is present in RA18,19, and strongly relates to systemic inflammation20, investigation of its role in response to therapy is warranted.

Epidemiological data suggest that both methotrexate (MTX)21 and anti-tumor necrosis factor-α (anti-TNF-α) therapy reduce CV mortality in RA22,23. Other groups have reported an improvement in surrogate markers of CVD and CV risk factors, such as macrovascular endothelial dysfunction24,25, arterial stiffness26, carotid intima-media thickness27, and insulin resistance28 after treatment with anti-TNF-α agents (particularly infliximab). It is not clear, however, whether the same results can be obtained in the microvascular circulation, and whether the improvement in vascular surrogate markers occurs in response to decreased inflammation in general or is a direct drug effect, particularly of TNF-α antagonists.

Our aim was to assess whether improvement in microvascular function in patients with RA was related to decreased inflammation and control of RA disease activity, or whether it was an effect of drug therapy per se. To do this we evaluated RA disease activity and microvascular endothelial function in “responders” [those achieving European League Against Rheumatism (EULAR) good response criteria29] compared to nonresponders to drug therapy.

MATERIALS AND METHODS

This was an open-label study carried out in Ninewells Hospital and Medical School, Dundee (clinical registration no. ISRCTN57761809). Fifty-one patients with RA meeting the 1987 American College of Rheumatology classification criteria for RA30 and with moderate or active disease as defined by the EULAR Disease Activity Score in 28 joints (DAS28)29 were recruited. Recruitment was of sequential patients attending the rheumatology outpatient clinics, who fulfilled the inclusion criteria, were about to start either MTX or an anti-TNF-α agent, and who gave written informed consent. Exclusion criteria included previous history of CVD, diabetes mellitus, uncontrolled hypertension or hypercholesterolemia, and any other inflammatory conditions.

Patients were given either MTX or anti-TNF-α [etanercept (ETA) or adalimumab (ADA)] therapy as part of their standard care after they failed to respond to adequate doses of, or had side effects to, a previous disease-modifying antirheumatic drug (DMARD), and were anti-TNF-naive. Treatment allocation was decided by rheumatologists in charge of patients’ care, based on patients’ clinical needs. Only when the treatment decision was made were patients invited to take part in the study. Doses of anti-TNF-α drugs were standard (ETA 25 mg twice a week or 50 mg weekly and ADA 40 mg every other week). Titration of MTX dose was decided by the rheumatologist responsible for the patient’s care and followed no specific dosing protocol.

The study was approved by the Tayside Committee on Medical Research Ethics and all patients gave written informed consent.

Clinical and laboratory measurements

Patients were assessed at baseline and at 2 and 4 months after starting antirheumatic therapy. During each visit a clinical evaluation was performed comprising measurements of height and weight, blood pressure (mean of 3 measurements taken on the left arm with the patient in seated position after 25 min rest), DAS28 [validated statistically derived disease activity index that combines 28 tender joint count, 28 swollen joint count, C-reactive protein (CRP), and a 100 mm general health visual analog scale (VAS)], and Stanford Health Assessment Questionnaire (HAQ; a validated questionnaire to assess quality of life and function in RA)31. Blood samples were taken for assessment of full blood count, CRP, and plasma viscosity (PV).

“Responders” were defined as patients who achieved the EULAR good response criteria (a reduction of DAS28 > 1.2 from baseline to the 4-month visit or a DAS28 ≤ 3.2 at 4 months)29. Nonresponders were defined as those who did not achieve this.

Assessment of microvascular function

Measurements of microvascular function were conducted in a laboratory with constant room temperature set at 22 ± 1°C and at the same time of day (1–3 PM). Patients were asked to refrain from smoking and drinking alcohol at least 10 hours and caffeine-containing beverages at least 3 hours before measurements. Subjects were studied in the supine position and were given a 30 min resting period. During measurements, subjects were asked to neither speak nor sleep.

Subjects were asked to lie in a supine position. After a 20 min rest, forearm microvascular function was assessed as described8,16,32,33, by measuring skin vascular responses to iontophoresis of 1% acetylcholine (ACh; Sigma-Aldrich Co. Ltd., Poole, UK) and sodium nitroprusside (SNP; David Bull Laboratories, Warwick, UK). ACh and SNP were both dissolved in deionized water to a concentration of 10 g/l (1%). Iontophoresis allows noninvasive delivery of drugs across the skin without inducing systemic effects. The volar aspect of the forearm was cleaned gently with adhesive tape, alcohol, and sterile water. The iontophoresis chamber (Moor Instruments, Devon, UK) consisted of a 20 mm internal diameter ring with a wire electrode running around the inner surface. The 2 chambers were fixed to the skin using double-sided adhesive tape and filled with 2 ml solution. The leads from the electrodes were connected to the iontophoresis controller. ACh and SNP were delivered simultaneously to the skin through the 2 separate iontophoretic chambers and using consecutive increases in anodal and cathodal current, respectively: 10, 15, 20, 50, and 100 μA. Two baseline scans of skin perfusion were taken before the iontophoresis protocol was administered. After the baseline scans, each dose was iontophoresed for approximately 200 s and 4 scans (each 50 s) were performed for each dose. Skin perfusion was measured using a laser Doppler imager (moorLDI, Moor Instruments, Axminster, UK). For each scan, the computer builds up a color-coded image termed laser Doppler flux and measured in perfusion units (PU), which represents skin blood flow over the scan area. The average of the last 2 stable scans was taken as the reading for that particular dose. Overall microvascular response for the total drug delivery period was determined by calculating the area under the perfusion × time curve (AUC) over baseline.

The perfusion response to the diluent only was not measured because previously, using large-diameter electrodes such as those in the present study, we did not elicit any nonspecific effect at the anodal electrode and a minimal effect at the cathode (which is negligible in comparison to the SNP response itself)34. Moreover, in other studies, where the authors subtracted the vehicle response, they found that this did not alter their conclusions33. The reproducibility of this technique in our hands is 11%16.

Statistical analysis

SPSS v15.0 for Windows was used for all statistical analyses. Results are presented as mean ± standard deviation. Data were checked for normality with the Kolmogorov-Smirnov test and parameters that were not normally distributed were log-transformed where this achieved normality. Analysis of variance (ANOVA) for repeated measures (including iontophoresis current and study visit) was used to compare the microvascular responses before and after treatment, followed by a modified post-hoc paired-sample t test at each dose when a significant difference was found. Independent-samples t tests were used to compare group differences. The relationship between quantitative variables was measured with Pearson’s correlation, and stepwise multiple regression analysis was used to determine the independent determinants of ACh area under the curve (AUC) and SNP AUC responses. P values < 0.05 were considered statistically significant. Power calculations were based on repeat microvascular responses measured at 2 timepoints at least 2 months apart in 44 individuals. The standard deviation (SD) of the change for the ACh response was 0.80. It was therefore possible to detect a difference of 0.5 SD (which equates to 13.4% change) with 80% power at p < 0.05 change using a paired comparison in 25 patients. A previous study with normal individuals by our group showed that n = 28 is sufficient to demonstrate improvements of 29% before and after intervention35.

RESULTS

Baseline

Fifty-one patients aged 31–75 years, 43 women and 8 men, were studied (the numbers selected for the study were based on our previous observations of responder and nonresponder rates to these drug therapies). Thirty-seven (72.5%) were rheumatoid factor (RF)-positive and 32 (63%) had erosive disease. The mean disease duration was 10 (SD 9.5) years. Thirty-nine (76%) patients were taking regular nonsteroidal antiinflammatory drugs (NSAID). Thirty-seven (72.5%) patients were already taking a DMARD at baseline, of which 10 (20%) were on combination therapy. The 2 most common DMARD were sulfasalazine (SSZ) and MTX (these latter were all in the group about to start a TNF-α inhibitor) taken by 23 (45%) and 19 (37%) patients, respectively. Eleven (22%) patients had hypertension that was well controlled with medication and all 4 (8%) patients that had hypercholesterolemia were receiving a statin. After the baseline visit, 27 patients were started on ETA by their rheumatologist, 3 on ADA, and 21 on MTX. Baseline characteristics of all patients are given in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of study patients.

As expected at baseline, significant differences were observed in disease duration (p < 0.0001), number of tender joints (p < 0.0001), DAS28-CRP (p < 0.0001), and HAQ (p < 0.0001) between the patients about to receive MTX and those starting TNF-α blockade. Twenty-three (74%) TNF patients were taking a DMARD at baseline (15 on MTX alone, 4 in combination with SSZ or hydroxychloroquine, and 4 monotherapy with other DMARD). The average weekly dose of patients’ MTX was 18 ± 5 mg. In the MTX group, 15 patients were taking SSZ, 1 combination therapy, and 5 were taking no DMARD. Baseline prednisolone dose was higher in the TNF than the MTX group but this difference was not statistically significant (1.6 ± 2.6 mg vs 0.5 ± 1.5 mg; p = 0.087; Table 1).

Baseline vascular responses to ACh and SNP, reflecting better vascular function, were significantly higher in the MTX group (ACh AUC 194,566 ± 83,165 and SNP AUC 139,963 ± 56,404) than in the TNF group (149,751 ± 76,409 and 91,854 ± 66,074) (p = 0.05 and p = 0.009; Table 1).

After antirheumatic treatment. All patients

By visit 2, the average dose of MTX in the MTX group was 12 ± 3 mg/week. This dose increased further by visit 3 (13 ± 5 mg/week).

For all patients, whether receiving MTX or TNF therapy, disease activity (DAS28-CRP) improved significantly from baseline (6.04 ± 1.18) to visit 2 (4.34 ± 1.34) and this improvement was maintained at visit 3 (4.0 ± 1.27) (p < 0.0001, ANOVA).

Reductions in levels of log10CRP (visit one 1.28 ± 0.44 mg/l, visit two 0.97 ± 0.44 mg/l, and visit three 0.92 ± 0.46 mg/l; p < 0.0001, ANOVA) and PV (1.8 ± 0.17 mPa.s, 1.72 ± 0.16 mPa.s, 1.75 ± 0.18 mPa.s; p < 0.0001, ANOVA) were also observed through the study period.

Although there was a trend toward improvement in the ACh and SNP responses from baseline to visit 2 and 3, this did not reach statistical significance (p = 0.250, ANOVA, and p = 0.062, ANOVA, respectively).

When the TNF and MTX groups were analyzed separately, although the ACh and SNP responses throughout the study were borderline significant in the TNF group they did not reach significance in either group (TNF ACh p = 0.122 and SNP p = 0.087; MTX ACh p = 0.836 and SNP p = 0.531; Figure 1). As shown in Figure 2, DAS28 decreased in the MTX and TNF groups from baseline to visit 3, but the drop in DAS28 score was significantly greater in the TNF group (TNF 2.49 ± 1.12 vs MTX 1.25 ± 1.64; p = 0.003).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A. ACh AUC in the 30 TNF (p = 0.122) and 21 MTX (p = 0.836) patients throughout the study. B. SNP AUC in the 30 TNF (p = 0.087) and 21 MTX (p = 0.531) patients throughout the study. Data are mean ± 95% CI.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

DAS28 in the 30 TNF and 21 MTX patients throughout the study. Data are mean ± 95% CI (TNF, p < 0.0001; MTX, p = 0.004).

DAS28 responders

Thirty-one patients (61%) [22 (81%) patients taking ETA, 2 (66%) of those on ADA, and 7 (33%) of those on MTX] achieved the EULAR response criteria by visit 3. At baseline, significant differences in the number of tender joints, DAS28-CRP, and HAQ score were observed between DAS28 responders and nonresponders — 19 ± 7 vs 12 ± 8 (p = 0.004); 6.46 ± 0.68 vs 5.39 ± 1.51 (p = 0.002); and 1.87 ± 0.52 vs 1.42 ± 0.84 (p = 0.014), respectively (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Disease activity scores and inflammatory mediators throughout the study in DAS28 responders and nonresponders.

When DAS28 responders were evaluated, there was a significant improvement in both the endothelium-dependent (p = 0.028, ANOVA; Figure 3) and endothelium-independent (p = 0.019, ANOVA; Figure 4) vascular responses from baseline to visit 2 and 3. A significant change in all the disease activity measures and inflammation was also observed from baseline to visit 3, as shown in Table 2.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Dose-dependent ACh responses in the 31 DAS28 responders throughout the study. Data are mean ± 95% CI (p = 0.028, ANOVA).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Dose-dependent SNP responses in the 31 DAS28 responders throughout the study. Data are mean ± 95% CI (p = 0.019, ANOVA).

Despite the statistically significant reduction in the number of swollen joints (p = 0.021) and DAS28-CRP (p = 0.023), no significant differences in endothelium-dependent (p = 0.833, ANOVA) and endothelium-independent (p = 0.915, ANOVA) vascular responses were observed throughout the study in DAS28 nonresponders.

Comparison between the DAS28 responders of the MTX and TNF groups was not possible due to the small numbers of responders in the MTX group. Although an improvement in the dose-dependent ACh and SNP responses of TNF patients was observed from baseline to visit 2 and 3, this did not reach statistical significance (p = 0.107 and p = 0.139, ANOVA, respectively).

Correlations

On univariate analysis at visit 3, ACh AUC and SNPAUC correlated with PV (r2 = 0.309, p = 0.032, and r2 = 0.371, p = 0.011, respectively) and as expected, with age (r2 = 0.449, p = 0.001, and r2 = 0.334, p = 0.020).

The variables tested in the model included age, sex, smoking habits, history of hypertension, RF positivity, body mass index, number of tender joints, number of swollen joints, log10CRP, DAS28 score, PV, and systolic and diastolic blood pressure. Forward stepwise multiple regression analysis revealed that PV (ß = −0.298, p = 0.029) and age (ß = −0.457, p = 0.001) were the only independent predictors of ACh AUC response, and that PV (ß = −0.500, p = 0.002) and DAS28 score (ß = 0.363, p = 0.02) independently predicted the SNP AUC response.

Adverse events

Three patients (6%) did not complete the study. All 3 patients were in the TNF group (2 started ETA and 1 ADA) and developed side effects after the 2-month visit. The patient starting ADA died from a combination of pulmonary fibrosis, infection, and pneumonitis that occurred 8 weeks after starting the ADA (added to a MTX regimen). One patient developed probable pulmonary fibrosis 8 weeks after starting ETA. He had concomitant MTX therapy (commenced 4 years earlier); he recovered shortly after stopping both drugs following a course of prednisolone. The third patient had worsening of mild congestive cardiac failure 10 weeks after commencement of ETA, and recovered satisfactorily after discontinuation of the TNF-α blocker and appropriate treatment for heart failure. These 3 patients were included in the baseline but not in the post-treatment analysis.

DISCUSSION

We demonstrated that in active RA, microvascular function is improved in those patients who respond to antirheumatic treatment, using the EULAR response criteria to define responders. This study strengthens the view that inflammation plays a key role in CVD and gives further evidence on the importance of tight and aggressive control of RA disease activity, not only to avoid further joint damage and disability, but to potentially reduce CVD risk.

Microvascular endothelial dysfunction has been implicated in the pathogenesis of several conditions such as diabetes mellitus, metabolic syndrome, and chronic renal failure. Abnormalities in the microvascular bed correlate with CV risk factors36–38 and established coronary artery disease39. Recently we showed a correlation between microvascular function in the forearm and coronary flow reserve in healthy subjects16. Indeed, the study of this vascular bed may provide distinct and additional information to that obtained through testing the macrocirculation, as microvascular dysfunction may in fact occur earlier17. Although macrovascular function may be a stronger determinant of future CV events, the correlation between microvascular function and the presence of CV risk factors is more robust12.

Microvascular dysfunction has been reported in RA18,19. It is associated with systemic inflammation40 and Datta, et al, in a pilot study, showed that in active RA, vascular function in the microcirculation can be improved with antiinflammatory treatment19. However, that study was small (8 patients) and disease activity was not measured, and it had variable timepoints and treatments that may have influenced the results. Further, it was not clear if this benefit was a drug effect or due to decreasing the inflammatory stimuli. Our study was carried out in 51 patients following power calculations to ensure adequate numbers of both responders and nonresponders, patients were treated with 2 different drug types (MTX and TNF-α blockade), assessments were done at 3 preplanned timepoints, and we measured several markers of inflammation and disease activity. Although a trend to improvement in vascular function was seen in the group as a whole, statistical significance was reached only in those that fulfilled the EULAR response criteria.

We found several differences between patients receiving MTX and those receiving anti-TNF-α drugs. At baseline, both groups seemed to represent distinct stages in the disease process, with those starting TNF-α blockade being at the severe end. Anti-TNF-α patients had longer duration of disease and more disease activity, and this was associated with significantly lower microvascular responses compared with MTX patients. Although not statistically significant, there was a trend toward better improvement in vascular function after TNF than after MTX treatment. Indeed, patients receiving TNF-blocking drugs were more likely to have a reduction in disease activity, and this reduction was greater than that observed in patients receiving MTX. Whether anti-TNF-α therapy possesses greater beneficial effects in vascular function than MTX or whether the trend toward better vascular function observed in anti-TNF-α patients was due to their greater antiinflammatory or other distinct properties remains unanswered; however, it is clear that uncorrected inflammation in the nonresponder group was paralleled by lack of improvement in endothelial function. In favor of the greater improvement in vascular function with anti-TNF-α therapy than with MTX would be the fact that TNF-α is a pivotal inflammatory cytokine directly involved in the pathogenesis of atherosclerosis; thus blocking this inflammatory mediator directly may be more effective in improving vascular health41,42. On the other hand, improvement in endothelial function has also recently been observed in RA patients refractory to TNF-α antagonists who were treated with rituximab; this was associated with a significant reduction in disease activity and CRP, suggesting that reducing inflammation may be the key factor43,44.

We have demonstrated a direct and independent correlation between microvascular function and inflammation (PV). This relationship was not found in the 2 previous studies assessing microvascular function in RA18,19 (probably due to their small numbers), but was in keeping with our findings in a previous study, where we reported CRP was an independent determinant of microvascular function40. This not only emphasizes the key role of inflammation in CVD, but also shows the importance that aggressive disease control may have in reducing this risk in patients with RA.

Most studies of macrovascular function in RA have shown evidence of endothelial-dependent but not independent vascular impairment in this group of patients. Moreover, after antiinflammatory treatment, improvement in endothelial-dependent but not independent function has also been observed18,24,25,45,46. The results at the level of the microcirculation, however, differ from these, not only because both endothelium-dependent and independent responses were found to be impaired in RA compared to healthy controls18,47 and because high CRP patients had lower ACh and SNP responses than low CRP patients20, but also because both in our present study and in the previous pilot study47, endothelium-dependent and independent responses increased significantly after antiinflammatory treatment. As reduced ACh responses reflect endothelial dysfunction, whereas impairment in SNP suggests a dysfunction at the vascular smooth-muscle level, it is possible that the vascular involvement of the microcirculation is more global (endothelium and vascular smooth-muscle), while in the macrocirculation the endothelium is mostly affected.

A limitation of our study was the open-label design that could have introduced treatment selection bias. This was a result of current UK prescription guidelines that state that only those RA patients with active disease who have failed to respond to 2 previous DMARD, one of which must have been MTX, are eligible to receive TNF-α blockers48. Allocation of treatment was, however, decided by the rheumatologist responsible for the patient’s care and not by the investigators. Moreover, previous studies on endothelial function used this same study design24,49.

We demonstrated that microvascular dysfunction is present in patients with active RA, that it correlates with systemic inflammation, and that it can be at least partially reversed with antirheumatic treatment, particularly in those patients who respond to it. As the anti-TNF-α drugs clearly showed the best antiinflammatory effect, we suggest that such drugs need to be assessed in early RA, as CV risk also occurs soon after diagnosis.

Acknowledgments

We are grateful to Gwen Kiddie for technical and administrative support.

Footnotes

  • Supported by Wyeth Pharmaceuticals. Prof. Belch also receives support from the Harkness Bequest and the Sir John Fisher Foundation.

    • Accepted for publication October 26, 2009.

REFERENCES

  1. 1.↵
    1. Myllykangas-Luosujarvi R,
    2. Aho K,
    3. Kautiainen H,
    4. Isomaki H
    . Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clinical Exp Rheumatol 1995;13:149–53.
    OpenUrl
  2. 2.↵
    1. DeMaria AN
    . Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89 Suppl 1:33–8.
    OpenUrl
  3. 3.↵
    1. Alkaabi JK,
    2. Ho M,
    3. Levison R,
    4. Pullar T,
    5. Belch JJ
    . Rheumatoid arthritis and macrovascular disease. Rheumatology 2003;42:292–7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. van Leuven SI,
    2. Franssen R,
    3. Kastelein JJ,
    4. Levi M,
    5. Stroes ES,
    6. Tak PP
    . Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008;47:3–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Vita JA,
    2. Keaney JF Jr
    . Endothelial function: a barometer for cardiovascular risk? Circulation 2002;106:640–2.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Gonzalez MA,
    2. Selwyn AP
    . Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115 Suppl 8A:99S–106S.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Celermajer DS,
    2. Sorensen KE,
    3. Gooch VM,
    4. Spiegelhalter DJ,
    5. Miller OI,
    6. Sullivan ID,
    7. et al.
    Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–5.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Newton DJ,
    2. Khan F,
    3. Belch JJ
    . Assessment of microvascular endothelial function in human skin. Clin Sci (Lond) 2001;101:567–72.
    OpenUrlPubMed
  9. 9.↵
    1. Dessein PH,
    2. Joffe BI,
    3. Singh S
    . Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634–43.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Belch JJ,
    2. Shaw JW,
    3. Kirk G,
    4. McLaren M,
    5. Robb R,
    6. Maple C,
    7. et al.
    The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997;95:2027–31.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Anderson TJ
    . Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007;115:2373–5.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Mitchell GF,
    2. Parise H,
    3. Vita JA,
    4. Larson MG,
    5. Warner E,
    6. Keaney JF Jr,
    7. et al.
    Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 2004;44:134–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Huang AL,
    2. Silver AE,
    3. Shvenke E,
    4. Schopfer DW,
    5. Jahangir E,
    6. Titas MA,
    7. et al.
    Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol 2007;27:2113–9.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Khan F,
    2. Green FC,
    3. Forsyth JS,
    4. Greene SA,
    5. Morris AD,
    6. Belch JJ
    . Impaired microvascular function in normal children: effects of adiposity and poor glucose handling. J Physiol 2003;551:705–11.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Shamim-Uzzaman QA,
    2. Pfenninger D,
    3. Kehrer C,
    4. Chakrabarti A,
    5. Kacirotti N,
    6. Rubenfire M,
    7. et al.
    Altered cutaneous microvascular responses to reactive hyperaemia in coronary artery disease: a comparative study with conduit vessel responses. Clin Sci (Lond) 2002;103:267–73.
    OpenUrlPubMed
  16. 16.↵
    1. Khan F,
    2. Patterson D,
    3. Belch JJ,
    4. Hirata K,
    5. Lang CC
    . Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clin Sci (Lond) 2008;115:295–300.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Philpott A,
    2. Anderson TJ
    . Reactive hyperemia and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007;27:2065–7.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Arosio E,
    2. De Marchi S,
    3. Rigoni A,
    4. Prior M,
    5. Delva P,
    6. Lechi A
    . Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 2007;25:1273–8.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Datta D,
    2. Ferrell WR,
    3. Sturrock RD,
    4. Jadhav ST,
    5. Sattar N
    . Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007;192:391–5.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Galarraga B,
    2. Khan F,
    3. Kumar P,
    4. Pullar T,
    5. Belch JJ
    . C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology 2008;47:1780–4.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Choi HK,
    2. Hernan MA,
    3. Seeger JD,
    4. Robins JM,
    5. Wolfe F
    . Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–7.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Dixon WG,
    2. Watson KD,
    3. Lunt M,
    4. Hyrich KL,
    5. Silman AJ,
    6. Symmons DP
    . Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Jacobsson LT,
    2. Turesson C,
    3. Gulfe A,
    4. Kapetanovic MC,
    5. Petersson IF,
    6. Saxne T,
    7. et al.
    Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213–8.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Hurlimann D,
    2. Forster A,
    3. Noll G,
    4. Enseleit F,
    5. Chenevard R,
    6. Distler O,
    7. et al.
    Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184–7.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Gonzalez-Juanatey C,
    2. Testa A,
    3. Garcia-Castelo A,
    4. Garcia-Porrua C,
    5. Llorca J,
    6. Gonzalez-Gay MA
    . Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51:447–50.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Maki-Petaja KM,
    2. Hall FC,
    3. Booth AD,
    4. Wallace SM,
    5. Yasmin,
    6. Bearcroft PW,
    7. et al.
    Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185–92.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Del Porto F,
    2. Lagana B,
    3. Nofroni I,
    4. Tinti F,
    5. Mitterhofer AP,
    6. D’Amelio R
    . Effects of tumour necrosis factor alpha blockade on lipid profile in active rheumatoid arthritis. Rheumatology 2007;46:1626–7.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Gonzalez-Gay MA,
    2. De Matias JM,
    3. Gonzalez-Juanatey C,
    4. Garcia-Porrua C,
    5. Sanchez-Andrade A,
    6. Martin J,
    7. et al.
    Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83–6.
    OpenUrlPubMed
  29. 29.↵
    1. van Gestel AM,
    2. Prevoo ML,
    3. van’t Hof MA,
    4. van Rijswijk MH,
    5. van de Putte LB,
    6. van Riel PL
    . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34–40.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Hagglund KJ,
    2. Roth DL,
    3. Haley WE,
    4. Alarcon GS
    . Discriminant and convergent validity of self-report measures of affective distress in patients with rheumatoid arthritis. J Rheumatol 1989;16:1428–32.
    OpenUrlPubMed
  32. 32.↵
    1. Spence VA,
    2. Khan F,
    3. Belch JJ
    . Enhanced sensitivity of the peripheral cholinergic vascular response in patients with chronic fatigue syndrome. Am J Med 2000;108:736–9.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Morris SJ,
    2. Shore AC,
    3. Tooke JE
    . Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995;38:1337–44.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Khan F,
    2. Newton DJ,
    3. Smyth EC,
    4. Belch JJ
    . Influence of vehicle resistance on transdermal iontophoretic delivery of acetylcholine and sodium nitroprusside in humans. J Appl Physiol 2004;97:883–7.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Khan F,
    2. Elherik K,
    3. Bolton-Smith C,
    4. Barr R,
    5. Hill A,
    6. Murrie I,
    7. et al.
    The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects. Cardiovasc Res 2003;59:955–62.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Khan F,
    2. Elhadd TA,
    3. Greene SA,
    4. Belch JJ
    . Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 2000;23:215–20.
    OpenUrlAbstract
  37. 37.↵
    1. Farkas K,
    2. Kolossvary E,
    3. Jarai Z,
    4. Nemcsik J,
    5. Farsang C
    . Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis 2004;173:97–102.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Khan F,
    2. Belch JJ
    . Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral L-arginine supplementation. J Rheumatol 1999;26:2389–94.
    OpenUrlPubMed
  39. 39.↵
    1. Ijzerman RG,
    2. de Jongh RT,
    3. Beijk MA,
    4. van Weissenbruch MM,
    5. Delemarre-van de Waal HA,
    6. Serne EH,
    7. et al.
    Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 2003;33:536–42.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Galarraga B,
    2. Khan F,
    3. Kumar P,
    4. Pullar T,
    5. Belch J
    . Microvascular dysfunction in rheumatoid arthritis [abstract]. Rheumatology 2008;46:ii6.
    OpenUrl
  41. 41.↵
    1. Galarraga B,
    2. Khan F,
    3. Kumar P,
    4. Pullar T,
    5. Belch JJ
    . Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009;48:1418–23.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Gonzalez-Gay MA,
    2. Garcia-Unzueta MT,
    3. De Matias JM,
    4. Gonzalez-Juanatey C,
    5. Garcia-Porrua C,
    6. Sanchez-Andrade A,
    7. et al.
    Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:373–9.
    OpenUrlPubMed
  43. 43.↵
    1. Gonzalez-Juanatey C,
    2. Llorca J,
    3. Vazquez-Rodriguez TR,
    4. Diaz-Varela N,
    5. Garcia-Quiroga H,
    6. Gonzalez-Gay MA
    . Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008;59:1821–4.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Kerekes G,
    2. Soltesz P,
    3. Der H,
    4. Veres K,
    5. Szabo Z,
    6. Vegvari A,
    7. et al.
    Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705–10.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Vaudo G,
    2. Marchesi S,
    3. Gerli R,
    4. Allegrucci R,
    5. Giordano A,
    6. Siepi D,
    7. et al.
    Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31–5.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Hansel S,
    2. Lassig G,
    3. Pistrosch F,
    4. Passauer J
    . Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003;170:177–80.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Datta D,
    2. Ferrell WR,
    3. Sturrock RD,
    4. Jadhav ST,
    5. Sattar N
    . Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007;192:391–5.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. National Institute for Health and Clinical Excellence
    . Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (final appraisal determination). [Internet. Accessed November 24, 2009.] Available from: http://guidance.nice.org.uk/download.aspx?o=388554
  49. 49.↵
    1. Gonzalez-Juanatey C,
    2. Llorca J,
    3. Sanchez-Andrade A,
    4. Garcia-Porrua C,
    5. Martin J,
    6. Gonzalez-Gay MA
    . Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006;24:309–12.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 3
1 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Improvement in Rheumatoid Arthritis Is Associated with Healthier Microvascular Function in Patients Who Respond to Antirheumatic Therapy
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical Improvement in Rheumatoid Arthritis Is Associated with Healthier Microvascular Function in Patients Who Respond to Antirheumatic Therapy
BERNAT GALARRAGA, JILL J.F. BELCH, TOM PULLAR, SIMON OGSTON, FAISEL KHAN
The Journal of Rheumatology Mar 2010, 37 (3) 521-528; DOI: 10.3899/jrheum.090417

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Clinical Improvement in Rheumatoid Arthritis Is Associated with Healthier Microvascular Function in Patients Who Respond to Antirheumatic Therapy
BERNAT GALARRAGA, JILL J.F. BELCH, TOM PULLAR, SIMON OGSTON, FAISEL KHAN
The Journal of Rheumatology Mar 2010, 37 (3) 521-528; DOI: 10.3899/jrheum.090417
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire